| Schedule of Revenue Recognition |
The
Company’s revenues consisted of the following:
Schedule
of Revenue Recognition
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
For the Three Months Ended | | |
For the Six Months Ended | |
| | |
June 30, | | |
June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Allergy Diagnostic Kit Sales | |
$ | 196,058 | | |
$ | 197,644 | | |
$ | 424,828 | | |
$ | 462,557 | |
| Integrated Service Program | |
| 491,399 | | |
| 263,628 | | |
| 865,900 | | |
| 426,130 | |
| Immunotherapy Treatment Sales | |
| 93,972 | | |
| 119,885 | | |
| 185,042 | | |
| 217,214 | |
| Clinical Study Revenue | |
| 29,700 | | |
| - | | |
| 29,700 | | |
| 89,100 | |
| Subscription Revenue | |
| 6,666 | | |
| 9,252 | | |
| 18,614 | | |
| 18,537 | |
| Shipping and handling | |
| 10,914 | | |
| 10,091 | | |
| 22,554 | | |
| 20,061 | |
| Training and Other Revenue | |
| 18,781 | | |
| 4,946 | | |
| 29,537 | | |
| 17,266 | |
| Total revenue | |
$ | 847,490 | | |
$ | 605,446 | | |
$ | 1,576,175 | | |
$ | 1,250,865 | |
|